跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
NEUTREXIN PWS IV 25MG/VIAL - Health Canada Drug Approval Details
Approvals
/
Health Canada
/
NEUTREXIN PWS IV 25MG/VIAL
Authorized
STANDARD
NEUTREXIN PWS IV 25MG/VIAL
MedImmune Oncology, Inc.
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
b8215ca053910d31
Company
MedImmune Oncology, Inc.
Type
Standard
Approval Details
Approval Id
b8215ca053910d31
Drug Approval Canada Name
NEUTREXIN PWS IV 25MG/VIAL
Product Name
NEUTREXIN PWS IV 25MG/VIAL
Status
Cancelled Post Market
Status Date
2007-02-21
Original Market Date
1994-12-31
Din
02065770
Drug Class
Human
Dosage Form
Powder For Solution
Route Of Administration
Intravenous
Schedule
Prescription
Ahfs
08:30.92
Atc Original
P01AX07 TRIMETREXATE
Atc Name
p 01 ax 07
Aig Number
0125420001
Company Name
MedImmune Oncology, Inc.
Company Address
One Medimmune Way, Gaithersburg, Maryland, United States, 20878
Company Detail Path
/organization/medimmune-oncology-inc
Company Information
Pharmaceutical Company Name
MedImmune Oncology, Inc.
Country Name
United States
Province Name
马里兰州
Active Ingredients
TRIMETREXATE (TRIMETREXATE GLUCURONATE)
25 MG / VIAL
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
b8215ca053910d31
Type
Standard
Back to Health Canada Approvals